What Is Arbutus Biopharma Corporation (ABUS) Worth in 2026?
According to the CirclFi Deep Alpha Valuation Engine, Arbutus Biopharma Corporation's intrinsic value is estimated at $1.89, suggesting the stock is overvalued at its current price of $4.56. With 7 out of 9 models flagging downside (-58.5% average return), the market may be pricing in unsustainable growth. Model dispersion is worth noting: First Chicago targets $4.54 (-0.5%), versus Sentiment SOTP at $0.20 (-95.5%). This +95.0% range highlights the importance of multi-model analysis rather than relying on any single methodology.
What Do the Models Say About ABUS?
9 of 13 models are currently active for ABUS. All 9 active models suggest the stock trades above fair value. The Bayesian DCF estimates ABUS's intrinsic value at $1.65, implying -63.7% downside from the current price. See which stocks rank higher →
How Does ABUS Rank in Biotechnology?
Among 76 Biotechnology stocks, ABUS ranks #12 by Quality of Company score. CirclFi's QOC score of 6.4/10 evaluates 32 fundamental signals. A score of 6.4 indicates above-average quality.
See all Most Undervalued Biotechnology Stocks →
As a biotechnology enterprise, Arbutus Biopharma Corporation operates in a sector where pipeline depth and stage distribution is a critical driver of valuation. Investors evaluating ABUS should weigh these sector-specific dynamics alongside our model-derived fair values.
Is ABUS a Value Trap?
CirclFi's Value Trap algorithm assigns ABUS a score of 38/100 (LOW). This indicates low risk. The financial profile does not exhibit typical value trap warning signs. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →
Multi-Model Methodology
9 of 13 models are active for Arbutus Biopharma Corporation. Moderate coverage provides meaningful perspective. Each model applies a fundamentally different valuation philosophy. See the complete methodology →
According to the CirclFi 32-factor quality framework, Arbutus Biopharma Corporation's fundamental quality profile registers 6.4/10. This respectable score captures the company's profitability depth, growth consistency, balance sheet resilience, and shareholder return track record.
The gap between the most bullish and bearish model spans +95.0% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →
Data Sources & Confidence
Every ABUS valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →
Across ABUS's 9 active models, average confidence is 27%. Lower confidence may reflect limited history or high volatility.
CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →
Buy with Gumroad